EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection

Modern Pathology

Volumn 25, Issue 4, 2012, Pages 548-555

  Chowdhuri, Sinchita Roy ^a   Xi, Liqiang ^a   Pham, Trinh Hoc Tran ^a   Hanson, Jeffrey ^a   Rodriguez Canales, Jaime ^a   Berman, Arlene ^a   Rajan, Arun ^a   Giaccone, Giuseppe ^a   Emmert Buck, Michael ^a   Raffeld, Mark ^a   Filie, Armando C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

cytology; EGFR; KRAS; laser capture microdissection; lung adenocarcinoma; mutation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER PATIENT; CELL ASSAY; CELL ISOLATION; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLOGY; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LASER CAPTURE MICRODISSECTION; LUNG ADENOCARCINOMA; MALE; ONCOGENE K RAS; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TUMOR CELL;

ADENOCARCINOMA; ADULT; AGED; BIOPSY, FINE-NEEDLE; DNA MUTATIONAL ANALYSIS; FEASIBILITY STUDIES; FEMALE; HUMANS; LASER CAPTURE MICRODISSECTION; LUNG NEOPLASMS; MALE; MARYLAND; MIDDLE AGED; MUTATION; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84859429097     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.184     Document Type: Article

References (40)

1. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-5909.
2. Jackman DM, Miller VA, Cioffredi LA, et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated nonsmall cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 2009;15:5267-5273.
3. West H, Lilenbaum R, Harpole D, et al. Molecular analysis-based treatment strategies for the management of non-small cell lung cancer. J Thorac Oncol 2009;4:S1029-S1039; quiz S41-2.
4. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-13311. (Pubitemid 39209661)
5. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139. (Pubitemid 38637993)
6. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500. (Pubitemid 38720929)
7. Janne PA, Engelman JA, Johnson BE. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 2005;23:3227-3234. (Pubitemid 46211347)
8. Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005;23:2493-2501.
9. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
10. Rosell R, Taron M, Reguart N, et al. Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway. Clin Cancer Res 2006;12:7222-7231. (Pubitemid 46095393)
11. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2:e17.
12. Massarelli E, Varella-Garcia M, Tang X, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007;13:2890-2896. (Pubitemid 46849563)
13. Malapelle U, Bellevicine C, Zeppa P, et al. Cytologybased gene mutation tests to predict response to antiepidermal growth factor receptor therapy: a review. Diagn Cytopathol 2011;39:703-710.
14. Nakajima T, Yasufuku K. How I do it-optimal methodology for multidirectional analysis of endobronchial ultrasound-guided transbronchial needle aspiration samples. J Thorac Oncol 2011;6:203-206.
15. Garcia-Olive I, Monso E, Andreo F, et al. Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations. Eur Respir J 2010;35:391-395.
16. Travis WD, Rekhtman N, Riley GJ, et al. Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. J Thorac Oncol 2010;5:411-414.
17. Sequist LV, Bell DW, Lynch TJ, et al. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007;25:587-595. (Pubitemid 350002967)
18. Clark DP. Seize the opportunity: underutilization of fine-needle aspiration biopsy to inform targeted cancer therapy decisions. Cancer Cytopathol 2009;117: 289-297.
19. Smouse JH, Cibas ES, Janne PA, et al. EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer Cytopathol 2009;117:67-72.
20. Asano H, Toyooka S, Tokumo M, et al. Detection of EGFR gene mutation in lung cancer by mutantenriched polymerase chain reaction assay. Clin Cancer Res 2006;12:43-48. (Pubitemid 43166174)
21. Janne PA, Borras AM, Kuang Y, et al. A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin Cancer Res 2006;12:751-758. (Pubitemid 43259854)
22. Smith GD, Chadwick BE, Willmore-Payne C, et al. Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis. J Clin Pathol 2008;61: 487-493. (Pubitemid 351518232)
23. Harrell JC, Dye WW, Harvell DM, et al. Contaminating cells alter gene signatures in whole organ versus laser capture microdissected tumors: a comparison of experimental breast cancers and their lymph node metastases. Clin Exp Metastasis 2008;25:81-88. (Pubitemid 351191228)
24. Emmert-Buck MR, Bonner RF, Smith PD, et al. Laser capture microdissection. Science 1996;274:998-1001. (Pubitemid 26398425)
25. Fend F, Raffeld M. Laser capture microdissection in pathology. J Clin Pathol 2000;53:666-672.
26. El-Serag HB, Nurgalieva ZZ, Mistretta TA, et al. Gene expression in Barrett's esophagus: laser capture versus whole tissue. Scand J Gastroenterol 2009;44:787-795.
27. Pan Q, Pao W, Ladanyi M. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn 2005;7:396-403. (Pubitemid 41149655)
28. Ogino S, Kawasaki T, Brahmandam M, et al. Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J Mol Diagn 2005;7:413-421. (Pubitemid 41149657)
29. Gandara DR, Lara Jr PN, Mack P, et al. Individualizing therapy for non-small-cell lung cancer: a paradigm shift from empiric to integrated decision-making. Clin Lung Cancer 2009;10:148-150.
30. Rivera MP, Detterbeck F, Mehta AC. Diagnosis of lung cancer: the guidelines. Chest 2003;123:129S-136S. (Pubitemid 36135710)
31. Boldrini L, Gisfredi S, Ursino S, et al. Mutational analysis in cytological specimens of advanced lung adenocarcinoma: a sensitive method for molecular diagnosis. J Thorac Oncol 2007;2:1086-1090. (Pubitemid 350307900)
32. Savic S, Tapia C, Grilli B, et al. Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers. Br J Cancer 2008;98:154-160.
33. Molina-Vila MA, Bertran-Alamillo J, Reguart N, et al. A sensitive method for detecting EGFR mutations in nonsmall cell lung cancer samples with few tumor cells. J Thorac Oncol 2008;3:1224-1235.
34. Marchetti A, Felicioni L, Buttitta F. Assessing EGFR mutations. N Engl J Med 2006;354:526-528; author reply-8.
35. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-144. (Pubitemid 41058345)
36. Quach N, Goodman MF, Shibata D. In vitro mutation artifacts after formalin fixation and error prone translesion synthesis during PCR. BMC Clin Pathol 2004;4:1.
37. Williams C, Ponten F, Moberg C, et al. A high frequency of sequence alterations is due to formalin fixation of archival specimens. Am J Pathol 1999; 155:1467-1471.
38. Li AR, Chitale D, Riely GJ, et al. EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. J Mol Diagn 2008;10:242-248. (Pubitemid 351692167)
39. Yasufuku K, Chiyo M, Koh E, et al. Endobronchial ultrasound guided transbronchial needle aspiration for staging of lung cancer. Lung Cancer 2005;50: 347-354.
40. Silvestri A, Colombatti A, Calvert VS, et al. Protein pathway biomarker analysis of human cancer reveals requirement for upfront cellular-enrichment processing. Lab Invest 2010;90:787-796.